Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2026 06:59 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052
December 19, 2025 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index
November 25, 2025 08:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 06, 2025 06:59 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 29, 2025 07:30 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Aclaris Therapeutics to Participate in Three November Healthcare Conferences
September 30, 2025 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Aclaris Therapeutics to Host In-Person and Webcast R&D Day in New York on October 14, 2025
September 09, 2025 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation at the 2025 European Academy of Dermatology and Ve
August 27, 2025 08:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics to Participate in Two September Healthcare Conferences
August 07, 2025 06:59 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
July 29, 2025 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of IT